On Tuesday, in the course of current trade, Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), gained 0.89%, and is now trading at $18.04.
Halozyme Therapeutics, declared interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.
The encouraging interim data was presented recently at the American Society of Clinical Oncology annual meeting in an oral presentation by Principal Investigator Sunil Hingorani, M.D., Ph.D., Associate Member of the Fred Hutchinson Cancer Research Center and Associate Professor at University of Washington School of Medicine.
The trial comprised of 135 treated patients in stage 1, of whom a total of 44 patients — 23 receiving PEGPH20 in combination with ABRAXANE® and gemcitabine (PAG treatment arm) and 21 receiving ABRAXANE and gemcitabine alone (AG treatment arm) — had accessible biopsies that were determined in a retrospective analysis to have high levels of hyaluronan (HA). PEGPH20 targets HA to assist improve cancer therapy access to tumor cells.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
During an Afternoon trade, Shares of SLM Corporation (NASDAQ:SLM), gained 0.24%, and is now trading at $10.34.
Sallie Mae, declared the winners of its first $20,000 “Good Things Come to Those Who Plan” contest, which awarded one grand prize of $10,000 and two second prizes of $5,000 each to families who are building financial plans to pay for college.
Families entered the contest by registering for any of Sallie Mae’s free plan-for-college tools, counting the College Planning Calculator and the Scholarship Search by Sallie Mae, and concluding a short essay on why they are excited to plan for college. The three winners were selected by a team of Sallie Mae employees, who judged the essays on a combination of statement of purpose and originality. More than 15,000 entries were presented.
The Ruse family from Lake Stevens, Wash., outside of Seattle, was named the $10,000 grand prize winner. Kyla Ruse, 17, was nominated by her mother, Angela Moore, who noted that Kyla will be the first in their family to graduate high school and go to college.
SLM Corporation, together with its auxiliaries, operates as a saving, planning, and paying for education company in the United States. The company offers private education loans to students and their families. It also provides banking products, such as high yield savings accounts, money market accounts, and certificates of deposits; and operates a consumer savings network that offers financial rewards on everyday purchases to assist families save for college.
Shares of ConocoPhillips (NYSE:COP), during its Tuesday’s current trading session gained 0.88%, and is now trading at $64.17.
ConocoPhillips, achieved a noteworthy milestone at its Surmont oil sands project in Canada with the on-plan start of first steam at phase 2 on May 29.
Surmont uses steam-assisted gravity drainage (SAGD) to recover the bitumen. This technique requires the reservoir to be heated with steam to allow the oil to flow. First steam is a noteworthy step toward production, or first oil, predictable by third quarter this year.
Production will ramp-up through 2017, adding about 118,000 barrels of oil per day (BOD) gross capacity. Total gross capacity for Surmont 1 and 2 is predictable to reach 150,000 BOD.
The Surmont project is located in the Athabasca Region of northeastern Alberta, Canada, about 35 miles (63 kilometres) southeast of Fort McMurray. Surmont is operated by ConocoPhillips under a 50/50 joint venture agreement with Total E&P Canada.
ConocoPhillips explores for, produces, transports, and markets crude oil, bitumen, natural gas, liquefied natural gas, and natural gas liquids worldwide. Its portfolio comprises shale and oil sands assets; lower-risk legacy assets in North America, Europe, Asia, and Australia; various international developments; and exploration prospects. ConocoPhillips was founded in 1917 and is headquartered in Houston, Texas.
Finally, Advaxis, Inc. (NASDAQ:ADXS), lost -2.29% Tuesday, hitting its highest level.
Advaxis, declared the clearance of the Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation’s (INCY) investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
In February 2015, Advaxis and Incyte reached a non-exclusive clinical trial partnership agreement to evaluate the combination of ADXS-HPV with epacadostat for the treatment of cervical cancer. The projected Phase 2 protocol is designed as a multicenter, open-label, preoperative window-study designed to evaluate the safety and efficacy of ADXS-HPV as monotherapy and in combination with epacadostat in about 30 patients with Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer. The results will be used to determine whether further clinical development of this combination is warranted.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
